ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oric Pharmaceuticals Inc (ORIC) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite analysts maintaining buy ratings and viewing the recent pullback as an overreaction, the lack of significant financial growth, insider and hedge fund selling trends, and ongoing legal investigations create substantial risks. The stock's technical indicators are neutral, and no proprietary trading signals suggest immediate action. Holding off for clearer positive catalysts or improved financial performance is recommended.
The MACD is above 0 and positively contracting, indicating a potential bullish trend. RSI is neutral at 48.195, and moving averages are converging, showing no clear direction. The stock is trading near its pivot level of 10.549, with support at 10.098 and resistance at 10.999.
The company's prostate cancer treatment rinzimetostat has shown a better safety profile compared to competitors, which could drive physician preference.
Insiders and hedge funds are significantly increasing their selling activity. The company is under investigation for potential securities fraud. Recent financial performance shows no revenue growth, a decline in net income, and worsening EPS. The stock also dropped significantly after failing to meet market expectations for its prostate cancer treatment.
In Q4 2025, the company reported no revenue growth (0% YoY), a 15.98% decline in net income to -$30.5M, and a 41.18% drop in EPS to -0.3. Gross margin remains at 0%.
Analysts maintain buy ratings despite recent setbacks, with price targets ranging from $17 to $25. They consider the recent selloff overdone and believe the company's treatment has a favorable safety profile, which could be a competitive advantage.
